NCT00655395 - Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

October 31, 2010

Conditions

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)

Interventions

DRUG

Laromustine (VNP40101M) and Ara-C

"1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."

Trial Locations (1)

10021

Weill Cornell Medical College, New York